Emergent BioSolutions (EBS) secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29M. The orders span several product offerings within Emergent’s medical countermeasures business, including countermeasures for smallpox, anthrax and botulism threats, and reflects the increasing priority governments are placing on defense and preparedness. This is the second procurement made this year by the same government. Emergent will receive approximately $26M in 2025, which is in addition to the more than $100M in sales already generated year to date for its MCM portfolio outside of the U.S.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions secures $17M contract modification from BARDA
- Emergent BioSolutions Secures $56 Million Contract Modification
- Emergent BioSolutions: Strategic Positioning and Contract Wins Support Buy Rating Despite Risks
- Emergent BioSolutions announces new contract modification for ACAM2000
- Emergent BioSolutions Advances Pediatric Botulism Antitoxin Study